Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”

Bibliographic Details
Main Author:	Manabu Kato
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	IJU Case Reports
Online Access:	https://doi.org/10.1002/iju5.12805
Tags:	Add Tag No Tags, Be the first to tag this record!

Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases
by: Daisuke Matsumoto, et al.
Published: (2025-01-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
by: Ella Xiaoyan Du, et al.
Published: (2024-08-01)

Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma
by: Christopher G. Fawsitt, et al.
Published: (2025-01-01)

Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
by: Jiwon Yang, et al.
Published: (2024-10-01)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
by: Mabel Ryder, et al.
Published: (2020-10-01)

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
by: Huaxiang Wang, et al.
Published: (2025-01-01)

Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study
by: Yu Lin, et al.
Published: (2024-11-01)

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
by: Lisha Li, et al.
Published: (2024-12-01)

Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
by: Yutaka Yoneoka, et al.
Published: (2024-11-01)

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial
by: Yaoping Shi, et al.
Published: (2024-12-01)

Sintilimab Plus Lenvatinib with or Without Radiotherapy for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis
by: Liu C, et al.
Published: (2024-11-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia
by: Gwo Fuang Ho, et al.
Published: (2024-12-01)

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
by: Liu DY, et al.
Published: (2024-11-01)

Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data
by: Bogdana Patachi, et al.
Published: (2025-01-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: G. Lyrarakis, et al.
Published: (2024-01-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
by: Chaoneng He, et al.
Published: (2024-01-01)

Tumor Lysis Syndrome Due to Pembrolizumab Use in Metastatic Nasopharyngeal Carcinoma
by: Aykut Turhan, et al.
Published: (2024-01-01)

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01)

Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review
by: Cheng Xue, et al.
Published: (2024-11-01)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
by: Chung-Wei Lee, et al.
Published: (2022-12-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
by: Xiaohui Zeng, et al.
Published: (2019-12-01)

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study
by: Ning Li, et al.
Published: (2024-11-01)

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by: Ilya Tsimafeyeu, et al.
Published: (2024-12-01)

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
by: Michela Roberto, et al.
Published: (2015-01-01)

The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma
by: Xinyi Zhang, et al.
Published: (2023-02-01)

Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases
by: Yaqing Kong, et al.
Published: (2025-12-01)

Pembrolizumab and axitinib induced pathological complete response in metastatic clear cell renal cell carcinoma with inferior vena cava thrombus: A case report
by: Ryan Wong, et al.
Published: (2025-01-01)

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
by: Miao-Zhen Qiu, et al.
Published: (2024-12-01)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
by: An Uche, et al.
Published: (2019-01-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
by: Christian Mueller, et al.
Published: (2020-10-01)

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations
by: Masato Kikuta, et al.
Published: (2025-01-01)

Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram
by: Yichen Wang, et al.
Published: (2024-11-01)

FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
by: Yu Ishizuya, et al.
Published: (2025-02-01)

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
by: Jun-Wei Wu, et al.
Published: (2024-12-01)

Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”

Similar Items

Similar Items